AKT in cancer: new molecular insights and advances in drug development

Prabhjot S. Mundi, Jasgit Sachdev, Carolyn McCourt, Kevin Kalinsky

Research output: Contribution to journalReview articlepeer-review

156 Scopus citations


The phosphatidylinositol-3 kinase (PI3K)–AKT pathway is one of the most commonly dysregulated pathways in all of cancer, with somatic mutations, copy number alterations, aberrant epigenetic regulation and increased expression in a number of cancers. The carefully maintained homeostatic balance of cell division and growth on one hand, and programmed cell death on the other, is universally disturbed in tumorigenesis, and downstream effectors of the PI3K–AKT pathway play an important role in this disturbance. With a wide array of downstream effectors involved in cell survival and proliferation, the well-characterized direct interactions of AKT make it a highly attractive yet elusive target for cancer therapy. Here, we review the salient features of this pathway, evidence of its role in promoting tumorigenesis and recent progress in the development of therapeutic agents that target AKT.

Original languageEnglish
Pages (from-to)943-956
Number of pages14
JournalBritish Journal of Clinical Pharmacology
StatePublished - Jan 1 2016


  • clinical oncology
  • medical oncology
  • phosphatidylinositol 3-kinases
  • protein kinase B
  • proto-oncogene proteins c-AKT
  • proto-oncogene proteins c-AKT/genetics
  • proto-oncogene proteins c-AKT/metabolism
  • proto-oncogene proteins c-AKT/physiology
  • signal transduction/physiology


Dive into the research topics of 'AKT in cancer: new molecular insights and advances in drug development'. Together they form a unique fingerprint.

Cite this